AI-generated analysis. Always verify with the original filing.
Coya Therapeutics, Inc. disclosed its fiscal year 2025 financial results, reporting collaboration revenue of $7.9 million, net loss of $21.2 million, R&D expenses of $16.7 million, and cash and cash equivalents of $46.8 million as of December 31, 2025. The company highlighted clinical progress on COYA 302 for ALS and FTD, scientific publications, a U.S. patent issuance, and $34.1 million in financings extending cash runway into 2H 2027.
Event Type
Disclosure
Mandatory
Variant
8-K
and Exhibit 99.1 hereto shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any g
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated March 16, 2026. 104 Cover Page Interactive Data File (embedded
| Metric | Value | Basis |
|---|---|---|
| Collaboration revenue | $7.9M | GAAP |
| Research and development | $16.7M | GAAP |
| In-process research and development | $2.3M | GAAP |
| General and administrative | $11.4M | GAAP |
| Total operating expenses | $30.5M | GAAP |
| Loss from operations | $-22.6M | GAAP |
| Net loss | $-21.2M | GAAP |
| Net loss per share of common stock, basic and diluted | $-1.27 | GAAP |